Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 702,770 |
Ending reported balance
After 2026-07-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-23 · Sale · Disposed 12,500 · Balance 715,270 F1: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Row 2 · 2026-07-24 · Sale · Disposed 12,500 · Balance 702,770 F2: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 117,028 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 117,028 F3: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. |
Filing footnotes · ownership attribution and instrument terms
F1: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 19, 2021 Filed Oct 21, 2021 20:33 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 7,445 | $27.85 | $207,343.25 |
DisclosureSEC source: 0001415889-21-004934 · form4-10212021_011011.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056,101 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $27.85, and the range of prices were between $27.60 and $28.00. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 22:19 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,000 | $26.30 | $315,600.00 |
DisclosureSEC source: 0001415889-21-004513 · form4-09212021_030906.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $25.95 and $26.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 19, 2021 Filed Aug 21, 2021 01:14 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,000 | $24.97 | $299,640.00 |
DisclosureSEC source: 0001415889-21-004029 · form4-08202021_060804.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $24.97, and the range of prices were between $24.75 and $25.46. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 21:29 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 4,123 | $25.63 | $105,672.49 |
DisclosureSEC source: 0001415889-21-003664 · form4-07212021_020727.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $25.63, and the range of prices were between $25.14 and $26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:29 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 7,877 | $24.83 | $195,585.91 |
DisclosureSEC source: 0001415889-21-003664 · form4-07212021_020727.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091,669 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $24.83, and the range of prices were between $24.75 and $24.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 23:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 600 | $26.30 | $15,780.00 |
DisclosureSEC source: 0001415889-21-003129 · form4-06212021_040621.xml · nonDerivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: 2. The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $26.19 and $26.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 23:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,990 | $25.59 | $50,924.10 |
DisclosureSEC source: 0001415889-21-003129 · form4-06212021_040621.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $25.59, and the range of prices were between $25.16 and $26.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 23:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 9,410 | $24.54 | $230,921.40 |
DisclosureSEC source: 0001415889-21-003129 · form4-06212021_040621.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,136 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $24.54, and the range of prices were between $24.18 and $25.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:31 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 122,028 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059971 · doc4.xml · derivative · entry 4 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 122,028 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:31 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 71,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059971 · doc4.xml · derivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:31 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 122,028 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059971 · doc4.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 122,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.direct: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:31 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 71,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059971 · doc4.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 23:43 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 179,340 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059512 · doc4.xml · derivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,340 Underlying: Common Stock · 179,340 shares Expires 2030-11-17 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 23:42 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 1,076 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059759 · doc4a.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,076 Underlying: Common Stock · 1,076 shares Expires 2030-11-17 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 12, 2020 Filed Nov 19, 2020 23:43 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 227,859 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-20-059512 · doc4.xml · derivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,859 Underlying: Common Stock · 227,859 shares Expires 2030-09-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from September 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 15, 2020 Filed Nov 19, 2020 23:43 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 143,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059512 · doc4.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,172 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.